Literature DB >> 34531443

Real-time quantitation of thyroidal radioiodine uptake in thyroid disease with monitoring by a collar detection device.

Prasanna Santhanam1, Lilja Solnes2, Tanmay Nath3, Jean-Paul Roussin4, David Gray4, Eric Frey2, George Sgouros2, Paul W Ladenson5.   

Abstract

Radioactive iodine (RAI) is safe and effective in most patients with hyperthyroidism but not all individuals are cured by the first dose, and most develop post-RAI hypothyroidism. Postoperative RAI therapy for remnant ablation is successful in 80-90% of thyroid cancer patients and sometimes induces remission of nonresectable cervical and/or distant metastatic disease but the effective tumor dose is usually not precisely known and must be moderated to avoid short- and long-term adverse effects on other tissues. The Collar Therapy Indicator (COTI) is a radiation detection device embedded in a cloth collar secured around the patient's neck and connected to a recording and data transmission box. In previously published experience, the data can be collected at multiple time points, reflecting local cervical RAI exposure and correlating well with conventional methods. We evaluated the real-time uptake of RAI in patients with hyperthyroid Graves' disease and thyroid cancer. We performed a pilot feasibility prospective study. Data were analyzed using R© (version 4.0.3, The R Foundation for Statistical Computing, 2020), and Python (version 3.6, Matplotlib version 3.0.3). The COTI was able to provide a quantitative temporal pattern of uptake within the thyroid in persons with Graves' disease and lateralized the remnant tissue in persons with thyroid cancer. The study has demonstrated that the portable collar radiation detection device outside of a healthcare facility is accurate and feasible for use after administration of RAI for diagnostic studies and therapy to provide a complete collection of fractional target radioactivity data compared to that traditionally acquired with clinic-based measurements at one or two time-points.Clinical Trials Registration NCT03517579, DOR 5/7/2018.
© 2021. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34531443      PMCID: PMC8446004          DOI: 10.1038/s41598-021-97408-y

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  13 in total

1.  Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.

Authors:  Arnaldo Moura-Neto; Camila Mosci; Allan O Santos; Barbara J Amorim; Mariana C L de Lima; Elba C S C Etchebehere; Marcos Antonio Tambascia; Celso Dario Ramos; Denise Engelbrecht Zantut-Wittmann
Journal:  Clin Nucl Med       Date:  2012-06       Impact factor: 7.794

Review 2.  Precision Medicine Comes to Thyroidology.

Authors:  Paul W Ladenson
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

3.  Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study.

Authors:  Peter Brinks; Koen Van Gils; Ellen Kranenborg; Jules Lavalaye; Dennis B M Dickerscheid; Jan B A Habraken
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-17       Impact factor: 9.236

Review 4.  Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.

Authors:  Vishnu Sundaresh; Juan P Brito; Zhen Wang; Larry J Prokop; Marius N Stan; Mohammad H Murad; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2013-07-03       Impact factor: 5.958

5.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

Authors:  Martin Schlumberger; Bogdan Catargi; Isabelle Borget; Désirée Deandreis; Slimane Zerdoud; Boumédiène Bridji; Stéphane Bardet; Laurence Leenhardt; Delphine Bastie; Claire Schvartz; Pierre Vera; Olivier Morel; Danielle Benisvy; Claire Bournaud; Françoise Bonichon; Catherine Dejax; Marie-Elisabeth Toubert; Sophie Leboulleux; Marcel Ricard; Ellen Benhamou
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

6.  Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves' disease.

Authors:  Yoshinori Osaki; Kanako Sakurai; Zenei Arihara; Masahiro Hata; Hiroshi Fukazawa
Journal:  Endocr J       Date:  2011-11-18       Impact factor: 2.349

7.  2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.

Authors:  Douglas S Ross; Henry B Burch; David S Cooper; M Carol Greenlee; Peter Laurberg; Ana Luiza Maia; Scott A Rivkees; Mary Samuels; Julie Ann Sosa; Marius N Stan; Martin A Walter
Journal:  Thyroid       Date:  2016-10       Impact factor: 6.568

8.  [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].

Authors:  M Watanabe; K Ito; T Mimura; N Ishikawa; E Ino; T Saitoh; H Tsuji; T Tsuchiya
Journal:  Kaku Igaku       Date:  1993-09

9.  Predictors of treatment failure, incipient hypothyroidism, and weight gain following radioiodine therapy for Graves' thyrotoxicosis.

Authors:  F W Gibb; N N Zammitt; G J Beckett; M W J Strachan
Journal:  J Endocrinol Invest       Date:  2013-04-30       Impact factor: 4.256

10.  High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover.

Authors:  Jeroen A F de Jong; Helena M Verkooijen; Gerlof D Valk; Pierre M J Zelissen; Bart de Keizer
Journal:  Clin Nucl Med       Date:  2013-06       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.